Coronary events with lipid-lowering therapy: The AFCAPS/TexCAPS trial [1] (multiple letters)

JAMA

Volumn 281, Issue 5, 1999, Pages 414-419

  Haq, I U ^a   Wallis, E J ^a   Yeo, W W ^a   Jackson, P R ^a   Ramsay, I E ^a   Krut, L H ^a   Kandzari, D E ^a   Goldschmidt Clermont, P J ^a   Mason, J M ^a   Freemantle, N ^a   McDiarmid, T D ^a   Hensel, W A ^a   Papadakis, J A ^a   Mikhailidis, D P ^a   Walsh, J ^a   Sigel, D ^a   Swislocki, A L M ^a   Downs, J R ^a   Gotto A M , Jr ^a   Clearfield, M ^a   Weis, S ^a   Rosenson, R S ^a   Tangney, C C ^a   more..

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN;

CLINICAL TRIAL; CORONARY RISK; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LETTER; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; TREATMENT OUTCOME; CORONARY ARTERY DISEASE; NOTE; RISK;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; LOVASTATIN; RISK;

EID: 0033518549     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.5.414     Document Type: Letter

References (0)